Bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks ligand–receptor interactions, induces receptor internalization and degradation, and engages immune effector functions (ADCC/ADCP).
Human bispecific IgG1 monoclonal antibody that targets EGFR and MET on tumor cells, blocking ligand binding and receptor phosphorylation, promoting receptor internalization and degradation to inhibit downstream signaling; additionally engages Fc-mediated immune effector functions (ADCC/ADCP) to kill target-expressing cells.
YES
DIRECT
Amivantamab binds MET on target cells and its Fc region engages immune effector cells (e.g., NK cells, macrophages) via Fcγ receptors, inducing ADCC and ADCP to kill MET-expressing cells; it also promotes receptor internalization/degradation and signaling blockade (antiproliferative).
BCMA-targeting antibody-drug conjugate that delivers the microtubule inhibitor MMAF to induce apoptosis and engages immune effector functions (ADCC/ADCP).
Afucosylated anti-BCMA monoclonal antibody linked to the microtubule inhibitor MMAF. After binding BCMA on malignant plasma cells and internalization, MMAF inhibits tubulin polymerization causing G2/M arrest and apoptosis; Fc effector engagement drives ADCC/ADCP for additional tumor cell killing.
YES
DIRECT
The anti-BCMA ADC binds BCMA, is internalized, and releases MMAF to inhibit tubulin, causing G2/M arrest and apoptosis; its afucosylated Fc also mediates ADCC/ADCP.
BCMA-targeting antibody-drug conjugate that delivers the microtubule inhibitor MMAF to induce apoptosis and engages immune effector functions (ADCC/ADCP).
Afucosylated anti-BCMA monoclonal antibody linked to the microtubule inhibitor MMAF. After binding BCMA on malignant plasma cells and internalization, MMAF inhibits tubulin polymerization causing G2/M arrest and apoptosis; Fc effector engagement drives ADCC/ADCP for additional tumor cell killing.
NO
INDIRECT
The ADC targets BCMA (not beta-tubulin); after BCMA binding and internalization, MMAF binds beta-tubulin to block microtubule polymerization, causing G2/M arrest and apoptosis, with added ADCC/ADCP. Cells expressing beta-tubulin alone are not specifically targeted or killed.
A chimeric IgG1 monoclonal antibody targeting EGFR that blocks ligand binding and downstream signaling and can induce antibody-dependent cellular cytotoxicity (ADCC).
Chimeric IgG1 monoclonal antibody against EGFR; binds the extracellular domain to block ligand binding, receptor activation and dimerization, inhibiting downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling to suppress tumor cell proliferation; Fc region can engage immune effector cells to induce ADCC.
YES
DIRECT
Cetuximab binds EGFR on target cells and its IgG1 Fc engages FcγR-expressing immune cells (e.g., NK cells) to mediate antibody‑dependent cellular cytotoxicity (and some complement activation), leading to lysis of EGFR-positive cells.
Anti-CD38 IgG1 monoclonal antibody that mediates ADCC, CDC, ADCP, and direct apoptosis, and depletes CD38+ immunosuppressive cells.
Human IgG1 monoclonal antibody targeting CD38 that induces tumor cell killing via ADCC, CDC, and ADCP and can trigger direct apoptosis; also depletes CD38+ immunosuppressive cells (e.g., Tregs, Bregs, MDSCs), enhancing antitumor immunity.
YES
DIRECT
Daratumumab binds CD38 on target cells and induces killing via Fc-mediated ADCC (NK cells), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and can trigger direct apoptosis upon binding/crosslinking.